coronaviru updat shutdown relax pipelin advanc
forecast drop base case includ
second-quart shutdown effect treatment second half
treatment base case
ask coronaviru
global crisi
epidemiolog societi respons
drug industri fit
assum avail least one
forecast hit
near-term hit global
conduct analyst govern
code ethics/cod conduct polici
secur trade polici equival
invest research polici inform
regard conflict interest pleas visit
reduc forecast due steepen govern respons
updat research dive unit state mitig strategi
monthli basi remaind also provid analysi recent data drug treatment
updat statu promis program
base-cas scenario assum full implement aggress social distanc measur
includ closur school nonessenti busi second quarter
think measur reced along first wave outbreak secondari wave
viru like much less deadli thank larg new drug treatment
key driver bear-cas scenario inefficaci new treatment countri like
south korea singapor appear brought viru control use aggress
econom destruct nonpharmaceut method believ may beyond abil
forecast real growth neg deduct impact
global expect declin impli recess par
forecast base detail scenario project industry-level impact mitig
strategi think scope shutdown order disrupt economi probabl overr
larg swath economi exempt order meanwhil histor larg fiscal
stimulu prevent collaps demand side economi
overal still expect modest long-run econom impact much less
impli drop global equiti sinc februari view
recess fit mold recess longer-last econom impact
exhibit forecast declin
page
coronaviru updat shutdown relax pipelin advanc march import disclosur end report
epidemiolog societi respons three scenario exhibit
base case probabl exhibit assum first wave subsid
end may mani social distanc measur closur school nonessenti
busi eas due exist least one effect treatment see page
still assum popul infect cours year base case
slightli higher averag death rate march analysi roughli
death rate first wave
relax social distanc base case mean one addit wave like
later howev secondari wave see much lower fatal rate around par
season flu thank new drug treatment plu quick diagnosi via prolif test
bull case probabl exhibit distinguish much lower infect rate
 popul account possibl success mimic tactic use
south korea singapor massiv test contact trace halt spread viru
scenario social distanc measur lift second quarter
bear case probabl exhibit assum current social distanc measur
modestli effect develop new drug treatment disappoint necessit
mainten busi closur stringent measur throughout
impact industri level analysi long-run impact
forecast impact real take probability-weight
averag across scenario exhibit deduct pre-covid expect result
forecast declin real recess slightli exce saw
though unpreced post-world war ii era
overal think main driver lower direct impact certain
industri via busi closur voluntari social distanc
expect indirect impact substanti basi point thank reduc spend
power econom confid think aggreg demand collaps critic
pass histor larg fiscal stimulu eclips post-great recess new deal-era stimulu
analysi industri level suggest even stay-at-home/shutdown order
implement state highli affect exhibit
consist busi larg exempt order implement state among
remain around half may abl continu normal econom activ via remot oper
use detail analysi benchmark updat global estim
forecast basi point impact world yield updat forecast neg
real growth think europ like hit somewhat harder due
possibl fiscal respons inadequ
even global like enter recess still forecast modest long-run impact
prior forecast still think larg fit mold v-
page
coronaviru updat shutdown relax pipelin advanc march import disclosur end report
sever mitig
exhibit takeaway coronaviru impact three scenario
time mitig
thousand american hit coronaviru wave log scale
indirect impact cap aggress fiscal stimulu
shutdown order implement state exempt economi
 highli
affect shutdown order
global enter recess
world region impact
 bureau econom analysi imf
page
coronaviru updat shutdown relax pipelin advanc march import disclosur end report
coronaviru analysi epidemiolog societi respons
first deep dive coronaviru discuss potenti durat sever impact
health economi higher level background diseas characterist well
burgeon pipelin vaccin treatment updat dive mitig
strategi monthli basi remaind updat assumpt sever
spread well lesson countri adapt also provid analysi
recent data drug treatment updat statu promis program
roughli american diagnos march march
start month see thousand new diagnos day
mani probabl infect undiagnos washington first state report case
januari hit hard although new york california also see rapid increas
case state could day behind trajectori pandem
prepar govern assum pandem month multipl
presid donald trump extend expir nation social distanc guidelin avoid
nonessenti travel restaur gather day march
day april given grim statist mani state move rapidli enforc aggress
mitig effort well beyond initi envis part march report
move contain effort commun mitig suppress current outbreak
includ cancel public gather close school mid-march howev
mani part countri also work home close nonessenti busi
led hardest-hit state like washington california new york mani state activ crisi
standard hospit anoth effort slow spread diseas reduc peak number
case without step would overwhelm healthcar system
think percentag american infect first wave viru
rel low pandem standard due aggress social distanc measur
wave last roughli three month expect wave outbreak base case
weather pattern wave mitig effort appli relax
author fine-tun effort contain diseas minim econom disrupt
think moder restrict second wave potenti treatment well
diagnost could wide avail could mean addit popul infect
time across scenario begin student return school septemb
scenario assum health impact coronaviru minim either due
effect vaccin erad viru
page
coronaviru updat shutdown relax pipelin advanc march import disclosur end report
moder second-wav shutdown enabl pipelin diagnost progress
base case assum first wave die aggress mitig measur spread
state come week strictest social distanc econom lockdown level
remain place countri april may specif decis typic made
state level sometim municip trump indic guidelin risk
categor state local level use diagnost data fit march
state-level social distanc implement vari level shown exhibit
exhibit mitig polici vari state march
close bar restaur
ia nb
ok sd
limit size gather
estim american
polici million
percentag
nyc nashvil flagstaff close bar restaur local mitig strategi
also assum pipelin diagnost progress june offer reassur govern
societi need begin reopen school busi summer although expect
american infect second potenti three-month wave begin start
school take us roughli end assum least one drug treatment option strong
diagnost test capac second wave patient diagnos rapidli upon
symptom treatment avail reduc cours sever ill
therefor think mitig measur moder easier initi maintain
necessari howev could vari across geographi depend state polici hospit system
demograph
still assum popul infect cours year base case
slightli higher averag death rate march analysi compar
analysi emanuel et al new england journal medicin infect rate could
roughli correspond social distanc reduc infect infect rate
predict social distanc imperi colleg respons
page
coronaviru updat shutdown relax pipelin advanc march import disclosur end report
assum death rate turn statist south korea south korea
aggress diagnost test rate like much relev actual fatal rate
countri seen fatal rate accord recent data extrapol base
death rate age group would lead roughli death rate
exhibit use south korea data estim potenti death rate use stratif
assum slightli higher death rate analysi impli around first wave hit
 assum hospit less prepar standard care still develop less
avail ventil drug therapi also assum diagnosi rate lag significantli
start case diagnos march base partli analysi estim
case diagnos china well analysi columbia estim
infect report march
even though expect mitig measur begin posit lag effect
come week assum ventil shortag state march play
new york april see follow section assum slow spread aggress
mitig measur march well somewhat noncompli american popul still lead
even higher infect rate april may viru roll differ state assum
roughli death rate second larger wave around level season flu due
treatment quick diagnosi still assum vaccin relev trajectori
diseas come play expect coronaviru recurr
coronaviru updat shutdown relax pipelin advanc march import disclosur end report
exhibit base-cas scenario assum slow effect mitig treatment
page
http //covidtrack com/data/ john hopkin center system scienc
engin
page
coronaviru updat shutdown relax pipelin advanc march import disclosur end report
hospit bed ventil shortag short base case
sever month bear
question whether enough hospit bed ventil handl surg demand
particularli level intensive-car unit open one alarm analysi
far almost million hospit bed roughli icu-level bed
mani alreadi use start pandem ventil requir mani
patient end icu also short suppli nurs respiratori therapist
monitor patient ventil roughli ventil ventil
manufactur like hamilton draegerwerk geting use produc roughli ventil
year global use doubl capac probabl best hope come month
addit enough nurs therapist monitor roughli patient
one estim publish health affair assum popul infect
occupi bed could freed patient conclud need spread infect
period order prevent far beyond capac month assum
infect rate number assum roughli patient requir icu think
analysi account aggress measur current take assum far
higher infect rate scenario first wave sever ventil need
highest
think ventil shortag limit base bull case could run sever month
bear-cas scenario exhibit show updat assumpt hospit rate
percentag patient need icu-level care ventil make simplifi assumpt
patient need ventil month mani need ventil sever week
matter day think shortag short-liv march-april outbreak first wave
creat local shortag base bull case ventil need averag
capac bear case assum need outstrip demand roughli four seven month
singl larger wave
exhibit ventil shortag temporari base bull last sever month bear
percentag total popul million
icu
patient
percentag
patient
durat
page
coronaviru updat shutdown relax pipelin advanc march import disclosur end report
analysi account creativ way boost suppli shortag could short-
live respons crisi manufactur like dyson also expect
produc low-end ventil help meet demand howev think import updat
food drug administr emerg use author march allow use
breath machin tool ventil includ anesthesia ga hardwar sleep apnea
machin posit airway pressur copd portabl oxygen gener also allow use air
tube splitter mean patient share ventil
bull case assum one wave due success contain surveil
busi larg reopen june
prior bull case death rate infect look overli optimist
increas death rate scenario higher base case appear
counterintuit assum higher concentr case first wave higher
death rate scenario second wave lower death rate scenario also
assum popul infect march analysi correspond
potenti reduct infect rate social would similar estim
infect rate wuhan china due effect social distanc assum time
peopl infect second wave diseas would minim spread
due wide use diagnost contact trace confirm infect find potenti
expos infect individu use surveil perhap cellphon data new app
develop assum could mimic tactic use success
singapor south korea given second chanc initi contain first wave
requir aggress widespread lockdown similar china less extrem busi
school would larg reopen first wave perhap limit busi closur
certain municip outbreak similar base case assum treatment becom
avail surveil creat less need still assum prophylaxi
vaccin antibodi see wider use
coronaviru updat shutdown relax pipelin advanc march import disclosur end report
page
http //covidtrack com/data/ john hopkin center system scienc
engin
page
coronaviru updat shutdown relax pipelin advanc march import disclosur end report
bear case assum longer econom shutdown late mitig lack pipelin progress
bear case assum recent shutdown nonessenti servic hardest-hit area
enough contain highli contagi viru due late nonuniform implement across
state recommend anthoni fauci chief medic advisor white hous
coronaviru task forc aggress measur like stay-at-hom order well public
hesit compli recommend start outbreak particularli region
hit later central state scenario case would overwhelm healthcar system without
effect treatment let go brake would slow process would take us
end year continu assum higher spread infect popul
increas assum death rate scenario due higher death rate
initi expect even geographi higher diagnosi rate like south korea well
assumpt care would sub-optimal scenario signific ventil shortag
sever month across countri assum rather two wave diseas take path
one extend larger wave
silver line higher infect rate higher number peopl emerg infect
antibodi viru recov patient help restart economi even
effect treatment vaccin fact germani expect issu immun certif
develop antibodi determin blood test could inform time
order remov variou part countri lockdown
coronaviru updat shutdown relax pipelin advanc march import disclosur end report
page
http //covidtrack com/data/ john hopkin center system scienc
engin
page
coronaviru updat shutdown relax pipelin advanc march import disclosur end report
lesson suppress mitig pandem
 delay base case assum act earli enough suppress
face pandem imperi colleg respons outlin potenti respons
govern take improv outcom basic strategi includ mitig reduc impact
protect high-risk individu suppress revers growth maintain low-level
infect rate exhibit detail action strategi conclus
team writer note intervent would probabl need two three week effect
becom notic icu case death rate given way diseas progress march
updat author clarifi suppress measur would ideal pair high level
diagnost test surveil well rapid isol case avoid resurg also
discuss idea earli implement suppress strategi death per
popul per week lead maximum reduct death rate began aggress
restrict around march time prior week death less
per popul mean maximum suppress still possibl
exhibit imperi colleg respons outlin polici
social distanc popul level
reduct contact rate
mitig could reduc healthcar demand death
healthcar system still overwhelm death rate like
unaccept mani high-incom countri
best strategi manag pandem combin polici
suppress viru although requir costli mainten
intermitt action roughli two third time trigger base
icu death rate sustain posit effect vaccin
avail action could adjust local level would like
involv month action
school closur help part broader effort
 public servic survey show link school closur
reduc case spanish flu without measur social distanc closur increas
exposur children expos extend famili home support data mitig strategi
control studi lower convict analysi past howev anoth studi
spanish reveal variat layer multipl social distanc measur led larg
page
coronaviru updat shutdown relax pipelin advanc march import disclosur end report
rang excess fatal per citi chicago mani citi
 prohibit public gather san francisco recommend resid wear mask earli
action multipl measur ban mass gather close school isol quarantin
led lowest mortal rate therefor see school closur part larger mitig effort
similarli center diseas control prevent indic short school closur
earli outbreak help longer closur week commun
spread could help combin mitig also think
school closur may necessari contain spread hong kongsingapor
success earli without close schoolsth fact work differ set tool
less advanc isol surveil well delay test made difficult judg
level commun spread date may add justif school closur
extrem mitig measur preced past centuri spanish flu
shown exhibit spanish flu asian flu quit differ
sever societi respons spanish flu sever led signific mitig measur
 citi exampl one analysi citi second wave spanish found
school closur ban larg gather much like today lockdown theater bar
indoor gather cancel groceri store open common combin
citi median length week week total analysi found new york
react quickli week isol quarantin well stagger busi
hour octob layer respons rel high infect death rate
pittsburg fare even wors late octob decis ban public gather initi
stop earli follow school closur end octob st loui layer school closur
larg gather ban week saw death rate popul versu doubl
pittsburgh author conclud layer effort significantli reduc death rate
especi action taken earli repeat anoth wave began contrast flu
pandem widespread deadli strategi reli wait vaccin
protect american came late affect trajectori diseas
page
coronaviru updat shutdown relax pipelin advanc march import disclosur end report
exhibit differ characterist respons toughest pandem centuri
caus pandem
vaccin treatment
entir new strain bird
human suscept
signific genet drift distinguish season flu
make larg part popul vulner
vaccin avail limit basi august septemb
avail broadli octob late
ye includ educ hygien decemb ban larg
gather close school household quarantin
vari time intens layer
st loui react earli layer pittsburgh react late
citi layer mitig effort earli fare better
particularli reintroduc effort upon next wave
still devast sever flu treatment
lack school closur drove acceler septemb
widespread sever
infect rate popul
us death popul
pandem asia earli success guid
coronaviru pandem process watch varieti mitig measur
play exhibit compar vulner sever countri hit action
took outcom far
countri act earli aggress diagnost mitig measur like
contact trace larg asia also germani abl prevent acceler case
contain viru china slowli emerg lockdown began jan last roughli
two month south korea abl avoid massiv lockdown cordon sanitair arm guard
surround infect area defin china contain coronaviru
european countri fast enough diagnost contain coronaviru start
still see uncertainti around viabil contact trace mani countri
earlier-hit countri also provid exampl valuabl tool could appli
contain viru broader costlier measur first wave
page
coronaviru updat shutdown relax pipelin advanc march import disclosur end report
exhibit vulner mitig polici outcom across europ asia
percentag popul
total test per million march
shutdown nonessenti busi
durat mitig effort
six-week test delay lack uniform social distanc across state could make flatten curv challeng
test younger popul aggress grid manag local govern halt viru
diagnost trace prevent acceler number new case import case drive new growth
earli aggress roadsid diagnost contact trace contain diseas
delay aggress action posit tough hit hospit
daili case grow given similar demograph respons european peer
younger infect heavi diagnost test contact trace improv germani outcom far still vulner
earli test demograph late social distanc hit itali hard although outbreak may peak
diagnost effort slow effect trace cluster school closur social obedi hygien slow case growth
spain late respons similar itali make particularli vulner
hong kong relax restrict earli march lock border march due import case
guangdong provinc critic care bed higher number icu bed
morningstar world data aha singapor ministri
countri broadli defin slower action
rapid action asia success contain viru nation gener move
slowli unit kingdom pivot prior mild recommend mid-march note
without social distanc near-term risk patient death overwhelm hospit
high school close march mid-march also start aggress action
mani european countri european countri shut nonessenti busi
mani state take action
page
coronaviru updat shutdown relax pipelin advanc march import disclosur end report
exhibit confirm cumul case countri day log scale start day case
western approach later less
mass quarantin enforc movement
stop short china lockdown
ecdc data march
demograph test rate partli explain death rate variat
success countri contain viru partli control death rate highli
variabl mani reason demograph key exampl one studi note fatal rate
itali actual quit similar china age itali case
patient age china older high-risk demograph
fit rel size popul list exhibit also itali reduc test
feb focu sever symptom push fatal rate ratio smaller
denomin perhap luck demograph germani outbreak much center
younger popul strong diagnost test could also help support much lower
death rate addit composit household vari greatli countri twice mani
live parent itali multigener famili facilit
household spread lead greater likelihood sever case concentr among older
page
coronaviru updat shutdown relax pipelin advanc march import disclosur end report
rapid action prevent outbreak singapor south korea critic
singapor one first countri stop flight wuhan januari develop respons
system sar epidem appli involv diagnosi isol infect
patient contact trace find other might expos quarantin
individu inform collect govern confirm case success trace
result address discov sourc case cluster publish ministri
among first patient identifi singapor identifi contact
singapor consid best respond contact trace
south korea larg cluster case around massiv outbreak daegu rapid action
diagnost contact trace quickli contain outbreak south korea diagnost test
percentag popul unparallel shown exhibit first case detect
day detect first case speed test also extraordinari
march south korea test citizen equival million american
test date beyond test south korea measur
aggress singapor school nonessenti busi close school break
extend march although student seoul expect return
distanc measur temperatur check april
page
coronaviru updat shutdown relax pipelin advanc march import disclosur end report
 diagnost capac pois increas dramat april
test critic piec prevent spread potenti eas aggress social
distanc shut economi improv test signific uncertainti
total number american infect coronaviru addit without broad
diagnost capac isol quarantin contact trace becom less use
 began test rate closer south korea initi rate end march
improv behind capac test patient day mid-march
becam capabl test patient day end
approv high-throughput test firm like roch thermo fisher abbott well test
commerci lab like labcorp quest test roughli million american march
expect test rate grow throughout year hundr thousand test per day
exhibit daili diagnost test march slow start improv rapidli
fda approv at-hom test everlywel plan begin suppli at-hom test
consum start march initi cover patient week week
long run test patient ship sampl lab turnaround howev plan
at-hom test broadli nix recent fda
page
coronaviru updat shutdown relax pipelin advanc march import disclosur end report
exhibit recent fda approv diagnost emerg use author
test
date eua
test work coba system high throughput test also ce mark
ship test per week capabl make million per month
initi million test stock produc million week ramp million
week april thermofish one largest diagnost provid coronaviru
high throughput panther fusion system like roch use smaller mid-siz lab
abl produc test per month start april
rt-pcr test firm abil perform test per day
march well initi capac march
capac per day march expect end week see enough
reagent test kit forese futur
abbott first clearanc firm ship test custom real-time
deploy system need test week end march
firm second approv id test confirm diagnosi five minut run
abbott portabl platform roll week march abbott plan ramp
portabl test per day total abbott produc million test april
minut test genexpert hardwar tabletop system us world-wide
accula devic min result point care
small california diagnost firm tripl staff product test day
china diagnost firm conduct coronaviru test central labss
china distribut kit per day
file emerg use march two-hour test would fastest work
handheld test similar strep
collabor california depart public health on-line screen test
support test region california first quickli hit capac
improv diagnost one import step think contact trace would necessari allow
full relax social distanc measur maintain contain viru best-cas
scenario contain viru may june appli contact trace allow
return busi usual part howev contact trace use sever
asian countri success cultur resist privaci compromis involv
govern access movement would imping privaci law firm
like googl facebook could also share anonym data could open lawsuit
page
coronaviru updat shutdown relax pipelin advanc march import disclosur end report
unless govern pass legisl protect anoth option provid app
mit privat kit allow user anonym contribut locat data make process
anonym voluntari howev research suggest contact need
trace effect similar estim coronaviru
bull case temporari local eas social distanc combin
better earli detect contact trace
given high level voluntari trace need order make contact trace success
nation assum situat bull-cas scenario probabl
abil reduc number case today depend aggress effort across countri
next sever week case eventu start declin new infect fall
low enough bull case assum begin follow rulebook countri like singapor
south korea aggress test continu isol quarantin voluntari contact trace
surveil allow gener popul return normal avoid anoth lockdown
bear case assum never achiev level control need implement
roll outbreak continu across countri throughout year particularli absenc
treatment base case avail treatment remov much fear fatal sever
case allow us return somewhat normal behavior despit continu infect progress
contact trace slower widespread enough prevent second wave perhap use
prevent futur outbreak beyond
even diagnost contact trace contain remain difficult
close watch recent uptick case hong kong singapor countri
struggl manag recent import case south korea also prepar begin lift restrict
april prevent import becam challeng viru went global initi focu
restrict travel china shift risk countri import case led rise
case broader measur countri like singapor decis close bar reduc
gather fewer begin march hong kong decis close border
nonresid maintain school closur april travel restrict within countri particularli
one larg could also necessari outbreak one citi could quickli seed
outbreak part countri overal continu expect form social
distancingsuch fewer larg gather work home less work travelcould
becom engrain societi next sever month even stricter measur like busi
closur stay-at-hom order relax
page
coronaviru updat shutdown relax pipelin advanc march import disclosur end report
drug industri fit
assum avail least one treatment base case
beyond nonpharmaceut intervent like diagnost contact trace lock
economi anoth key element evolut pandem potenti pharmaceut
intervent progress treatment prevent exhibit detail on-going
studi timelin potenti data
exhibit on-going coronaviru clinic studi watch
three arm two dose
either mcg mcg
mcg
repurpos drug compar studi
cansino three arm one dose
patient
part test fever
part adapt design test
effect fatal need
ventil oxygen
high dose iv placebo
remdesivir use permit
standard care
lopinavir/ritonavir lop/rit
losartan arb blood
pressur relax blood
iv daili day
iv daili day
iv daili day
iv day
iv day
 minnesota
 oxford
prophylaxi health care
treatment prevent
treatment mild
 minnesota hospit patient
nation institut
allergi infecti
lab-confirm
one criteria
countri
 minnesota
 minnesota
 nebraska
page
coronaviru updat shutdown relax pipelin advanc march import disclosur end report
one import distinct pandem pandem treatment time
spanish flu influenza viru even isol patient given
vaccin late impact trajectori diseas first flu
treatment tamiflu relenza approv make easier patient toler symptom
also improv outcom tamiflu also reduc complic like pneumonia lead
hospit death addit postexposur prophylaxi significantli reduc chanc
get flu studi household contact seven day tamiflu prophylaxi among household
member within two day symptom first infect member reduc confirm flu case
placebo group tamiflu group treatment also stockpil
spark avian swine flu fear
think gilead novel antivir remdesivir best shot efficaci coronaviru gilead
provid patient remdesivir compassion use other qualifi
clinic trial discuss march report antivir test ebola patient
offer reassur safeti shown efficaci preclin model mer addit
initi encourag stori use patient albeit data control
studi yet shown exhibit polymeras replic machin viru highli
similar sar gilead posit data anim model remdesivir sar drug
meant trick polymeras think remdesivir piec genet code realli
stop signal prevent replic infect
exhibit data gilead remdesivir limit encourag
patient start treatment day ill day day condit improv supplement oxygen
stop
patient receiv remdesivir compassion use near death verifi posit test right
start drug day infus patient began improv well
controversi potenti safeti issu patient receiv remdesivir
three transient gi symptom temporari elev aminotransferas level signal liver damag
patient nejm highlight patient patient patient recov think small sampl
extrem ill patient make difficult pinpoint caus safeti issu transient liver enzym elev
seen phase ebola healthi volunt patient ebola lab
abnorm seen
first us
publish detail scarc wall street journal report half american
diamond princess critic ill averag age recov two week sinc start
remdesivir treatment japan none die march encourag
typic high death rate among older critic ill patient close china
sourc cite compani report fiercebiotech endpoint
page
coronaviru updat shutdown relax pipelin advanc march import disclosur end report
on-going control trial see exhibit read posit april gilead confid dosag
optim time treatment biggest question becom suppli suppli constraint like
mean remdesivir much impact death rate next month two
howev think treatment lower death rate potenti second wave
fall gilead offer specif feb call financi result alreadi begun
manufactur risk gilead tri increas suppli trial make liquid freeze-dri
form drug ad manufactur partner manufactur drug in-hous
assum firm could enough suppli treat sever patient next
month would broader suppli avail fall part base-cas
scenario allow less aggress social distanc becom accept risk
late march variou drug repurpos new york state deal largest
outbreak countri initi focu combin malaria drug antivir properti
hydroxychloroquin antibiot azithromycin drug purchas larg
quantiti state new york observ studi regimen control arm
help us gather data efficaci safeti regimen control trial also
progress test malaria drug anoth variat chloroquin
fda decid grant emerg use author hydroxychloroquin chloroquin
phosphat march allow use drug patient qualifi clinic trial
data yet larg control studi fda note reason believ
drug could effect potenti benefit outweigh
exhibit summar take data complet chloroquin studi well studi
antivir flu drug avigan arbidol hiv drug kaletra antibodi includ anti-inflammatori
drug antibodi recov patient overal skeptic abil hiv
therapi much efficaci coronaviru given data far arbidol data
disappoint howev avigan data promis chloroquine-bas regimen could also
effect among repurpos approv drug encourag potenti
antibodi actemra kevzara help patient sever respiratori distress addit
coronaviru antibodi recov patient could highli effect difficult scale larg
number patient includ potenti antivir anti-inflammatori therapi exhibit
mani seen encourag preclin data indic efficaci china
page
coronaviru updat shutdown relax pipelin advanc march import disclosur end report
exhibit beyond remdesivir mix data report far coronaviru repurpos antivir antibodi
hydroxychloroquin
march china studi hydroxychloroquin day versu placebo mild patient
show clearanc rate treatment placebo significantli differ durat
hospit neg nucleic acid compar arm time normal temp compar
radiolog progress placebo control patient usual receiv antivir like hiv drug
kaletra flu drug arbidol hydroxychloroquin patient got arbidol patient receiv ifn-beta
muddi data
french studi hydroxychloroquin azithromycin earli march daili hydroxychloroquin use
azithromycin well includ asymptomat patient upper respiratori lower respiratori tract
infect treat patient signific reduct viral load day compar control much
lower durat carri viru much effici clear combin hydroxychloroquin
reduc length time patient contagi posit day control
combin antibiot azithromycin led cure rate day hydroxychloroquin alon
howev potenti cardiac toxic combo qt prolong need watch trial
data patient appear point faster viral clear day vs day control arm improv chest
symptom improv control conduct rel healthier patient pt studi
doctor saw higher recoveri rate reduc fever/cough data patient china show better
respiratori improv faster viral clear given drug signific side effect
accord zhang xinmin china scienc technolog ministri
china control studi test lopinavir/ritonavir arbidol monotherapi mild moder patient
compar placebo patient control group recov faster differ seen cough chest
ct scan lopinavir patient see advers event treatment gi liver enzym elev
patient progress sever critic statu studi includ patient lopinavir
overal kaletra studi fail significantli improv symptom boost surviv reduc viru level howev
kaletra studi detail show patient given treatment earlier within day symptom start roughli half
mortal rate versu standard care
china studi indic kaletra arbidol patient normal temperatur median day
control patient normal temperatur day patient median viral clearanc day differ
diseas progress ct scan day
elacoi studi mild moder patient benefit seen either arm versu control arm
time viral clear gi symptom cough chest ct side effect almost quarter lopinavir/ritonavir
patient small studi discourag lopinavir could need higher dose side effect issu
single-arm studi china peer review conclud drug actemra target regeneron
kevzara could role drive inflammatori immun respons caus acut respiratori distress
syndrom ard critic ill patient trial patient saw rapid fever reduct
patient saw reduc need oxygen within day receiv actemra
creat use plasma recov patient patient access hour single-us emerg ind
jama publish studi march sever ill patient recov use convalesc plasma
standard hyperimmun also develop plasma firm
sourc cite compani report fiercebiotech endpoint
page
coronaviru updat shutdown relax pipelin advanc march import disclosur end report
exhibit repurpos antivir develop coronaviru
 donat hiv drug chines hospit clinic test warn use larg
unsupport base sar efficaci
hiv drug combo began trial china coronaviru februari formal author treat pneumonia
caus coronaviru china donat suppli enforc global patent right data late januari
hand patient support efficaci although nejm-publish lotu studi appear significantli improv
condit sever ill patient control studi reduc viral load earli treatment within day onset appear
reduc mortal post-hoc analysi
flu drug recommend chines author test alon kaletra medicin
ganovo danoprevir ascleti pharma
approv japan china flu avigan also use guinea ebola gener china test zhejiang
hisun inhibit rna polymeras like remdesivir show better efficaci fewer side effect kaletra multipl
studi includin one shenzhen hospit also test mild patient japan recommend
countri health minist potenti birth defect could limit wide use
gener malaria drug immun system modul target antivir -- also use treat autoimmun condit
first report highli effect vitro china studi use off-label treatment mani countri
bayer donat tablet brand version resochin us march although suppli could tricki
sourc pakistan gener manufactur also donat suppli us novarti could donat tablet
end may dose patient manufactur ramp teva march april data
studi mix encourag particularli safer hydroxychloroquin combin antibiot
azithromycin large-scal prevent studi ny-bas treatment studi start late march look like
potenti regimen facilit faster recoveri reduc chanc spread other
proteas inhibitor design treat hiv clinic tral china report success hand patient
also test combin
exhibit repurpos anti-inflammatori drug develop coronaviru
use treat arthriti also tamp immun system danger cytokin storm cancer patient car-t cancer
treatment also trigger actemra also studi patient respiratori distress due coronaviru
recommend china nation health commiss march roch announc phase trial covacta march
roch also suppli vial us strateg nation stockpil
given interest target peer actemra base proof concept china kevzara trial began march
hospit patient data come week month trial outsid began enrol
approv treatment autoimmun diseas interferon studi potenti support care coronaviru
could stimul infect patient mount respons synairgen announc phase trial march copd
investig treatment special ifn-beta formul inhal drug help lung recoveri asthma
patient cold flu infect
announc march studi hyper-inflammatori syndrom base emerg data use hospit itali
announc march studi hyper-inflammatori syndrom base emerg data use hospit itali
hudson medic sponsor compassion use studi alexion complement inhibitor complement system
shown caus immun system overreact damag coronavirus studi
stroke drug also known tpa could help sever ill patient respiratori distress block format
blood clot impair lung function although bleed known risk drug sever pandem could also
use altern ventil shortag continu
page
coronaviru updat shutdown relax pipelin advanc march import disclosur end report
weigh strong platform technolog rapid speed develop
fact approv rna vaccin manufactur speed uncertain
vaccin instruct bodi make spike protein coronaviru necessari membran
fusion host cell infect also target past mer sar vaccin design
protein creat immun respons got fund program coalit
epidem prepared innov also six vaccin clinic made initi vaccin
suppli new norwood massachusett facil first trial start earli march
ship nation institut allergi infecti diseas day sequenc
select record vaccin first patient dose march trial involv
two-shot seri healthi volunt data three month follow six- eight-
month phase test hundr thousand point vaccin could produc broader
use ceo stephan bancel said emerg use vaccin could avail like
healthcar worker fall ahead approv assum least year vaccin could
becom wide avail time potenti season coronaviru becom season
even data posit later year manufactur like delay releas ramp
manufactur allow million dose per month timelin still vagu
sever vaccin move forward lead candid shown exhibit
cansino vaccin enter test china march among potenti large-cap pharma entrant
johnson johnson risen lead expect push vaccin develop
septemb could billion dose avail around end year focu
mrna similar approach peer like curevac enter trial late april partner
enter trial summer partner sanofi expect
vaccin also potenti hundr million billion dose particularli
curevac self-amplifi technolog multipl success stori would increas global suppli
expect data second half broader avail
expect modest price level initi treatment vaccin moderna ceo bancel impli
price higher respiratori vaccin prevnar pneumococc vaccin
roughli four low end medicar reimburs flu vaccin roughli
tamiflu stockpil cost govern less per said emerg use
vaccin would provid not-for-profit basi lead us believ price probabl
person well provid billion dose earli
page
coronaviru updat shutdown relax pipelin advanc march import disclosur end report
first dose administ wuhan march cansino work academi militari medic scienc
institut vaccin dose first patient march patient quarantin day
administr first patient temporari side effect like fever diarrhea cansino technolog reli
adenovirus-bas viral vector vaccin platform led approv ebola vaccin china year
concept rapid review vaccin replication-defect adenoviru type vector express sars-
spike protein adenovir vector great tool vaccin gene therapi patient could pre-
 review sar mer vaccin candid shelv coronaviru efficaci use differ viral construct
select candid march firm steadili acceler develop plan recent move
estim phase start earli novemb septemb latest data avail year also acceler
suppli estim initi estim million dose year month larger quantiti earli
billion dose end readi emerg use earli
sanofi work barda vaccin use influenza flublok technolog could enter clinic autumn
receiv approv month fall technolog proven capac dose
year sanofi also enter collabor mrna vaccin could clinic trial end
avail end translat vaccin manufactur gram scale
manufactur batch per month could add suppli mid-level dose could vaccin
million peopl per month initi hundr million end sanofi help
medicago plant-bas technolog allow develop vaccin week receiv genet sequenc viru
advanc develop overal pipelin season flu vaccin review approv
canada manufactur palnt could serv dose annual complet medicago expect start
phase vlp juli august
work cepi curevac two mrna candid target spike protein pois enter trial summer
curevac mrna self-amplifi reduc amount vaccin need manufactur three approv
manufactur suit could make million dose per campaign fourth suit would push north billion curevac
receiv fund european commiss march
offici announc plan start trial late april develop start europ us
china fosun china right biontech sign letter intent march elsewher expand flu
vaccin partnership coronaviru polymun self amplifi could potent
requir smaller dose advantag manufactur vaccin
support cepi continu mers-bas partnership posit data inovio plan
start clinic studi china start june partner beij advaccin manufactur tx-base vgxi
howev firm acceler develop march aim move test april volunt firm
made dose plan produc one million dose end
target antibodi promis treatment prevent assum broad avail end
sever firm work develop antibodi lab protect patient viru treat
sever ill patient prevent ill patient progress sever stage even remdesivir
fail develop antibodi treat prevent diseas could allow us emerg
initi shutdown abil prevent futur one pharmaceut intervent dose
small percentag popul could prevent spread avian flu tamiflu estim
million peopl time broader avail novel target antibodi treatment
highli uncertain although timelin acceler lead program firm like regeneron
page
coronaviru updat shutdown relax pipelin advanc march import disclosur end report
